Engflag

Clindac -A

Quick links to important sections

Clindac -A

Clindac -A_DE

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clindac -A

Quick Facts

Property Description
Active Ingredient Clindamycin (as Clindamycin phosphate)
Form Topical solution, Gel, Cream, or Lotion
Pharmacological Class Lincosamide antibiotic / Antimicrobial agent
Common Use Dermatological agent for bacterial skin issues
Origin Semi-synthetic (derivative of Lincomycin)

What Type of Medicine is Clindac-A?

Clindac-A is a prescription-only medication that features Clindamycin (Clindamycin phosphate) as its active ingredient. This compound is classified as a semi-synthetic Lincosamide antibiotic, characterized by its unique structure and mechanism. It is designated as a specialized dermatological agent for managing skin conditions where bacterial proliferation is a key concern.

As a single active ingredient product, Clindac-A is designed exclusively for topical administration, which represents a differentiating factor from systemic oral antibiotics. It is available in multiple dosage forms, including a liquid topical solution, a gel, a cream, or a lotion, offering formulation flexibility to suit varying skin types and application areas. This non-systemic approach emphasizes the localized treatment of the skin.

Clindamycin's General Action and Dermatological Role

The general purpose of Clindac-A is to function as a targeted antimicrobial agent that manages undesirable bacterial populations on the skin. Clindamycin achieves this through its established role as a protein synthesis inhibitor, which is a mechanism that restricts bacterial growth. Specifically, the action achieves a bacteriostatic action against susceptible organisms, such as Cutibacterium acnes, which is frequently involved in Acne vulgaris.

By controlling the bacterial load, this topical preparation is central to supporting the alleviation of intensity in inflammatory skin lesions. The overall role is to contribute to the resolution of lesions by mitigating the bacterial component, serving as an educational example of how targeted topical therapy is prioritized for localized dermatological needs.

Regulatory References

  1. Clindamycin
  2. Lincosamide antibiotic
  3. bacteriostatic action
  4. Acne vulgaris

What side effects are possible with Clindac -A?

Possible Side Effects and Safety Information

The regulatory documentation for topical clindamycin phosphate identifies two primary categories of documented adverse events: localized skin reactions and systemic gastrointestinal disturbances. The latter arise from the potential for the antibiotic to be absorbed from the skin surface, a factor critical to the overall safety profile.

Adverse Reaction Classification

The most frequent reactions observed are local effects at the application site. Regulatory documents classify several effects by frequency:

Classification Examples of Reactions
Very Common (ge 1/10) Dryness, Peeling, Erythema (Redness), Burning sensation, Itching, Oily skin.
Common (ge 1/100 to <1/10) Skin irritation, Urticaria (Hives).
Not Known Pseudomembranous colitis, Diarrhea, Folliculitis, Contact dermatitis.

Gastrointestinal and Systemic Safety Concerns

The most serious safety concern documented in official warnings is colitis, including pseudomembranous colitis. This risk is associated with the systemic absorption of the antibiotic and may be characterized by severe persistent diarrhea and abdominal cramps. While rare with topical use, this risk mandates specific contraindications against use in individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Colitis has been observed to begin up to several weeks following the cessation of therapy.

Population-Specific Notes

The medicine is also associated with specific safety constraints. For nursing mothers, the drug may appear in breast milk and has the potential to cause adverse effects on the infant’s gastrointestinal flora. Furthermore, the safety and effectiveness in pediatric patients under the age of 12 have not been established in regulatory documents.

Overdose and Emergency Response

The official regulatory documents on topical clindamycin emphasize that the medicine carries a potential for sufficient systemic absorption if excessive quantities are applied. This level of absorption can lead to adverse effects typically associated with oral or intravenous administration, which forms the basis of the official overdose profile.

The most severe documented outcome associated with clindamycin absorption is colitis, including pseudomembranous colitis, which regulators note may range in severity from mild diarrhea to a fatal outcome. Clinical manifestations of this severe complication often involve diarrhea or bloody diarrhea. Localized overuse may also present as irritant dermatitis.

Regulatory guidance mandates specific actions in the event of an overdose or suspected systemic effect. The drug must be discontinued immediately if significant diarrhea occurs. Furthermore, immediate medical attention is required—including contacting emergency services—if an accidental ingestion overdose leads to acute systemic signs such as seizure, collapse, or trouble breathing. Management procedures are generally limited to symptomatic and supportive measures, with specific diagnostic monitoring, such as large bowel endoscopy, potentially required to confirm colitis in severe cases. No specific antidote is explicitly documented in the official labeling for this overdose scenario.

Therapeutic Uses of Clindac -A

What Clindac-A Treats: Main Uses and Benefits

Managing Inflammatory Acne and Bacterial Load

Clindac-A is used for the topical management of acne. It is applied to address inflammatory or irritative states of the skin, particularly when symptoms are acute or disruptive. The treatment focuses on managing the physiological strain caused by red, swollen, and sometimes painful manifestations, such as papules and pustules. By addressing these symptoms, the medication provides supportive relief and helps ease the overall symptom burden associated with inflammatory skin conditions.

The primary therapeutic focus is on conditions involving recurrent or episodic manifestations, including Acne vulgaris and certain forms of superficial bacterial folliculitis. It is used to manage symptoms that may become intense or disruptive to the skin's surface.

“The supportive application during these phases contributes to improved day-to-day comfort.”

Addressing Symptom Severity and Recurrence

Clindac-A is relevant for skin conditions characterized by periods of heightened symptoms, and it is commonly used to help manage mild to moderate acne. It plays a role in managing symptom clusters, especially those linked to recurring breakouts on the face, chest, or back. Its use assists with maintaining functional skin stability and supports comfort during episodes of heightened irritation.

Quick Fact: Relief for Inflammatory Symptoms
Primary Symptom Focus Redness, swelling, and pain in papules and pustules.
Typical Severity Mild to moderate acne, or as supportive therapy for severe cases.
Patient Benefit Supports day-to-day comfort and helps manage recurrent symptom patterns.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Clindac-A is subject to strict population eligibility rules defined by official regulatory authorities. The medicine is contraindicated and must not be used by individuals with a history of hypersensitivity to clindamycin or the related antibiotic, lincomycin. Use is also strictly prohibited in patients with a history of specific gastrointestinal diseases, including regional enteritis, ulcerative colitis, or any form of antibiotic-associated colitis.

Age-Related Eligibility and Restrictions

Safety and effectiveness for Clindac-A have been formally established in patients 12 years of age and older for the treatment of acne. The medicine's use is not established in pediatric patients under the age of 12. Furthermore, clinical data on older adults (age 65 and over) is limited, as trials did not include sufficient numbers of subjects from this group.

Conditional Use Populations

Use during the first trimester of pregnancy is conditional and recommended only if clearly needed. For nursing mothers, regulatory guidance mandates a decision to discontinue nursing or discontinue the drug due to the potential for adverse effects on the infant. Caution is also advised for atopic individuals and patients receiving neuromuscular blocking agents.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Clindamycin (the active ingredient in Clindac-A) details several documented restrictions and pharmacokinetic considerations based on regulatory labeling.

Documented Pharmacodynamic and Metabolic Interactions

Co-administration with Erythromycin-containing products is restricted due to a demonstrated in vitro antagonism between the two agents. Clindamycin also possesses neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents (NMBAs) and may antagonize the effects of anticholinesterases.

From a pharmacokinetic perspective, Clindamycin is metabolized primarily by CYP3A4 and CYP3A5. Therefore, co-administration with strong CYP3A4/5 inhibitors may reduce clearance and increase systemic exposure, while strong inducers (such as Rifampicin) may increase clearance, potentially leading to a loss of effectiveness.

Contraindication and Coagulation Risk

In the event of severe antibiotic-associated colitis, antiperistaltic agents are formally contraindicated. Co-administration with Vitamin K Antagonists (e.g., Warfarin) has been associated with officially reported outcomes of increased coagulation tests (PT/INR) and a risk of bleeding.

Timing and Topical Constraints

The regulatory profile specifies a 3-day separation period is required before and after administration of the oral Typhoid Vaccine to avoid diminishing its effectiveness. Concomitant use with other topical acne therapies should be done with caution due to the risk of a cumulative irritancy effect on the skin.

Mechanism of Action

Inhibition of Essential Bacterial Protein Synthesis

Clindamycin's primary action is exerted after the inactive Clindamycin phosphate prodrug undergoes local enzymatic hydrolysis by skin phosphatases to become the active Clindamycin base. The active base engages the core microbial machinery by binding to the 23S ribosomal RNA within the bacterial 50S ribosomal subunit. This molecular interaction prevents the elongation of polypeptide chains, thereby arresting the synthesis of proteins required for cell growth and multiplication. This yields a bacteriostatic outcome, leading to the physiological consequence of limited Cutibacterium acnes propagation.

Modulation of Local Inflammation

Separate from its antimicrobial role, the molecule acts as a modulator of the host's inflammatory response. It directly influences cellular recruitment by inhibiting the chemotaxis (migration) of inflammatory immune cells, primarily neutrophils, toward the affected tissue. This suppression of cellular signaling results in a physiological attenuation of local inflammatory processes, which restrains the magnitude of the tissue's inflammatory response. Resistance can limit this mechanism if C. acnes modifies its ribosomal target, preventing effective binding.

Dosage and Administration Information

How to Use Clindac-A

This section describes the high-level, standardized usage principles for topical clindamycin (Clindac-A).

Administration Scope

The medicine is strictly for topical administration, meaning it is for external use only on the skin. The general principle of administration involves covering the entire affected area with a thin film of the product, rather than spot-treating individual lesions.

Feature Detail
Route of administration Topical (External cutaneous use only)
Dosing schedule Apply a thin film to the entire affected area.
Frequency pattern Typically twice daily (morning and evening) for the single-agent solution, gel, and lotion forms.

Procedural and Age-Group Rules

Preparation for Use:

Before application, the area of skin intended for treatment must be cleansed and dried. Specific handling is required for certain forms; for example, the lotion must be shaken well immediately prior to each use to ensure proper consistency. The medicine must not be allowed to contact sensitive surfaces, including the eyes, mouth, nose, and other mucous membranes.

Age-Group Administration:

The standard twice-daily regimen is used for adults and adolescents 12 years of age and older. For children under 12 years of age, the appropriateness of use and the specific dose must be determined by a healthcare provider, as safety and effectiveness in this younger population have not been uniformly established.

Connection to the Overall Use Protocol:

The administration protocol structures the use of this medicine as a localized, two-step daily regimen. The instructions define the required external route, the preparation of the site, the standard coverage area, and the mandated frequency, establishing a standardized procedure that is followed regardless of the specific topical dosage form.

Recent Clinical Evidence

Research evidence / Overview of studies for Clindac -A

Evidence for use in Mild to Moderate Acne Vulgaris

This section will summarize the structure of the clinical evaluation, detailing the types of randomized controlled trials (RCTs) and systematic reviews used, and which key outcomes, such as lesion counts and global assessments, were measured in adult and adolescent populations.

The primary evidence base for topical clindamycin was studied in the context of Acne Vulgaris that is categorized as mild to moderate. Research examined this medicine through multi-center, randomized, double-blind, vehicle-controlled clinical trials. These types of studies are applied in research contexts involving fluctuating or unstable symptoms and research often utilizes for evaluating initial changes. The populations observed included adolescents 12 years of age and older and adults who presented with the condition.

In these trials, researchers explored outcomes linked to inflammatory or irritative states. Studies monitored changes in the symptoms by precisely measuring the absolute number of inflammatory lesions (papules and pustules) and non-inflammatory lesions (comedones) over defined time intervals. Findings describe patterns observed in the studies related to these lesion counts, which help contextualize how the visible symptoms evolved in the observed populations during the short-term research period.

Evidence from Comparative Studies

This section will describe the research design used to compare the medicine against vehicle controls (placebo) and will outline the specific metrics used to assess differences between the treatment groups in pivotal trials.

The pivotal clinical studies were designed as vehicle-controlled trials. Reports described patterns observed in the treatment group compared to the vehicle group regarding changes in lesion counts and the overall Investigator's Global Assessment (IGA) rating. Studies reported that a higher proportion of individuals in the active medicine group achieved the specific success criteria defined by the IGA compared to patterns observed in the vehicle-only group. This evidence contributes to understanding symptom patterns over the initial short-term research phase.

Research on Long-Term Outcomes and Follow-up

This section will outline the maximum duration of follow-up observed in the clinical development program and describe the scope of data available regarding outcomes beyond the typical short-term pivotal trial period.

The majority of studies conducted were designed to observe responses over a defined short-term time interval, typically around 12 weeks. While this duration accounts for the research on initial symptom changes, the follow-up durations were limited considering that acne is a condition characterized by fluctuating or episodic manifestations over time. However, long-term effects are not fully established. Research describes studies, but data for monitoring physiological strain or stress over many months remain insufficient.

What the Scientific Literature Indicates as Research Gaps

This section will summarize the key areas of uncertainty documented in authoritative sources, including research limitations concerning long-term safety and the potential for bacterial resistance.

Scientific literature highlights the potential for the development of bacterial resistance to the medicine. This finding has led research to explore whether co-administration with other agents may help mitigate the risk of resistance. Additionally, the safety and effectiveness research for this medicine has not been formally evaluated in children younger than 12 years.

Key Studies & References

  1. Acne vulgaris: management - NICE Guideline NG198 (September 2021, relevant to resistance and combination therapy)

Frequently Asked Questions (FAQ)

Common questions about Clindac -A (FAQ)

Q: What is antibiotic resistance and how does it relate to using Clindac -A for acne?

A: Clindamycin is an antibiotic that works by controlling bacterial populations on the skin. Regulatory documents state that when antibiotics are used, there is a potential for antibacterial resistance to develop. This finding is related to the potential for the drug’s effectiveness to change over time, and official product information highlights this risk.

Q: Can I apply moisturizer right after I put on Clindac -A?

A: Regulatory guidance indicates the medicine is applied to clean, dry skin. Official product information cautions that using this product concurrently with other topical preparations, including non-medicated cosmetics, should be done with care. This is to avoid a potential increase in skin irritation.

Q: How is the use of Clindac -A generally classified during pregnancy?

A: Use of the medicine during pregnancy is officially recommended only if clearly needed. Historically, the active ingredient has been classified by the FDA as Pregnancy Category B, meaning animal studies did not show a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Official documents advise professional consultation regarding use during this time.

Q: Are there special considerations for using Clindac -A while breastfeeding?

A: Clindamycin is excreted in human milk. Regulatory guidance notes the potential for the infant to experience adverse effects on their gastrointestinal flora. Regulatory guidance advises that a decision should be made to either discontinue nursing or discontinue the drug.

Q: Is it normal to feel a mild burning or stinging when first applying Clindac -A?

A: A burning sensation at the application site is an expected and frequent side effect, classified in regulatory documents as a 'Very Common' adverse reaction. If this sensation is severe or worsens, it is a key reason for further professional evaluation.

Q: Can Clindac -A be used at the same time as Benzoyl Peroxide?

A: The regulatory profile specifies that co-administration with other topical acne therapies should be done with caution due to the risk of a cumulative irritancy effect on the skin. Official regulatory information suggests that any combination use requires a professional assessment.

Q: What is the maximum duration of continuous use for Clindac -A generally recommended in official sources?

A: While the time to see full improvement can take 8 to 12 weeks, official guidance indicates that continued daily use may be necessary for months or even longer in some cases to maintain control of the condition. Regulatory sources emphasize that treatment is generally re-evaluated periodically.

Q: Is it necessary to use a daily sunscreen when using Clindac -A?

A: Non-clinical studies noted that a similar clindamycin formulation caused a shortening of the time to tumor onset in hairless mice exposed to simulated sunlight. Official documents suggest sun protection should be a point of discussion with a healthcare provider, especially due to general skin sensitivity during acne treatment.

Q: Can I use products containing AHAs or BHAs (like glycolic or salicylic acid) while using Clindac -A?

A: Official warnings advise using caution with abrasive or medicated soaps and skin products that contain alcohol. This caution applies to skin products that contain alcohol, as well as medicated or abrasive cleansers, because they may cause increased skin irritation when combined with topical clindamycin.

Q: How long does it usually take to see initial improvement after starting Clindac -A?

A: In clinical trials, full improvement with Clindac -A was typically observed after 8 to 12 weeks of treatment. The 8- to 12-week timeframe is the period monitored in clinical trials for the medicine to show its full effect.

Q: Is Clindac -A intended for long-term use, or is it typically a short-course treatment?

A: The treatment is intended to control the condition, and official sources indicate that use may need to continue for months or even longer to maintain the benefits. Regulatory materials suggest that treatment is generally re-evaluated after the initial period to determine continued appropriateness.

Q: Does the effectiveness of Clindac -A decrease over time if used for a long period?

A: The potential for the development of antibacterial resistance is a documented risk associated with extended use of clindamycin. This risk is why regulatory guidance suggests that the duration of therapy should be periodically reviewed.

Q: Can using Clindac -A cause the skin to become more oily instead of dry?

A: Both oily skin and dryness are listed as very common adverse reactions in regulatory documentation. This indicates that the medicine may cause oiliness in some individuals, while others may experience dry skin.

Q: Can Clindac -A be used by older adults (geriatric population)?

A: Official product information states that clinical trials did not include sufficient subjects aged 65 and older to establish a definitive difference in response. Consequently, the safety and effectiveness have not been formally established in this older population.

Q: Does Clindac -A affect the skin's sensitivity to cold or windburned conditions?

A: In clinical settings involving combination clindamycin products, patients are advised that weather extremes, such as cold or wind, may cause increased irritation to the skin during treatment. Skin treated with the medicine may therefore be more sensitive to harsh elements.

Q: What is the distinction between topical Clindamycin and oral Clindamycin for acne?

A: Both the topical and oral forms of clindamycin are absorbed systemically. However, the most severe safety concern, pseudomembranous colitis, is mainly associated with the orally or parenterally administered forms of the drug, though the risk exists with topical use due to systemic absorption.

How should Clindac -A be stored and disposed of?

Storage and Disposal of Clindac-A Topical Gel

Official regulatory information for clindamycin phosphate topical gel defines mandatory storage and disposal protocols to maintain product stability.

Storage Requirements

Clindac-A must be stored at Controlled Room Temperature, typically mathbf20 C to 25 C (68 F to 77 F), with temporary excursions permitted. It is a strict regulatory requirement to protect the product from freezing because freezing may alter its efficacy. The gel must also be stored away from direct sunlight and moisture. As a standard safety measure, all medicine must be kept out of the reach of children and pets.

Disposal Instructions

Unused or expired Clindac-A must be discarded properly. The used container, including any remaining contents, can typically be placed in a suitable container and disposed of in the household trash, following standard protocol for most topical medications.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clindac -A found in:

A-Z Index: